|
|
News Breaks
|
November 5, 2009
|
| 16:33 EDT |  | THRX |
| theflyonthewall.com: | Theravance and Astellas announce commercial launch of VIBATIV | | Theravance and Astellas Pharma announced the commercial launch of VIBATIV, or telavancin in the U.S. On September 11, the F.D.A. approved VIBATIV for the treatment of adult patients with complicated skin and skin structure infections, or cSSSI, caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant, or MRSA, and methicillin-susceptible, or MSSA, strains. VIBATIV is a bactericidal, once-daily injectable lipoglycopeptide antibiotic discovered by Theravance. :theflyonthewall.com |
|
|
News For THRX From The Last 14 Days Check below for free stories on THRX the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 9, 2012
|
| 16:22 EDT |  | THRX |
|
|
January 31, 2012
|
| 11:21 EDT |  | THRX |
| | 10:28 EDT |  | THRX |
| | 06:11 EDT | | THRX |
| theflyonthewall.com: | Theravance initiated with an Underweight at Morgan Stanley | | Target $12. :theflyonthewall.com |
|
|
|
|
|
Subscribe for More Information